Adventures in vascular biology: A tale of two mediators

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 361, Issue 1469, 2006, Pages 735-759

  Moncada, S ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Aspirin; Cardiovascular pathology; Free radicals; Nitric oxide; Oxidative stress; Prostacyclin

Indexed keywords

CARDIOVASCULAR DISEASE; NITRIC OXIDE; PATHOLOGY;

EID: 33845236186     PISSN: 09628436     EISSN: None     Source Type: Journal    
DOI: 10.1098/rstb.2005.1775     Document Type: Review

References (247)

1. Akarasereenont, P., Techatraisak, K., Thaworn, A. & Chotewuttakorn, S. 2000 The induction of cyclooxygenase-2 by 17beta-estradiol in endothelial cells is mediated through protein kinase C. Inflamm. Res. 49, 460-465. (doi:10.1007/s000110050617)
2. Alderton, W. K., Cooper, C. E. & Knowles, R. G. 2001 Nitric oxide synthases: structure, function and inhibition. Biochem. J. 357, 593-615. (doi: 10.1042/0264-6021:3570593)
3. Almeida, A., Moncada, S. & Bolanos, J. P. 2004 Nitric oxide switches on glycolysis through the AMP protein kinase and 6-phosphofructo-2-kinase pathway. Nat. Cell Biol. 6, 45-51. (doi:10.1038/ncb1080)
4. Amezcua, J. L., O'Grady, J., Salmon, J. A. & Moncada, S. 1979 Prolonged paradoxical effect of aspirin on platelet behaviour and bleeding time in man. Thromb. Res. 16, 69-79. (doi: 10.1016/0049-3848(79)90270-6)
5. Amezcua, J.-L., Palmer, R. M. J., de Souza, B. M. & Moncada, S. 1989 Nitric oxide synthesized from L-arginine regulates vascular tone in the coronary circulation of the rabbit. Br. J. Pharmacol. 97, 1119-1124.
6. Antithrombotic Trialists' Collaboration 2002 Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br. Med. J. 321, 71-86.
7. Asselbergs, F. W., van der Harst, P., Jessurun, G. A. J., Tio, R. A. & van Gilst, W. H. 2005 Clinical impact of vasomotor function assessment and the role of ACE-inhibitors and statins. Vasc. Pharmacol. 42, 125-140. (doi:10.1016/j.vph.2005.01.009)
8. Axelrod, L. 1983 Inhibition of prostacyclin production mediates permissive effect of glucocorticoids on vascular tone. Perturbations of this mechanism contribute to pathogenesis of Cushing's syndrome and Addison's disease. Lancet 1, 904-906. (doi:10.1016/S0140-6736(83)91330-2)
9. Azuma, H., Ishikawa, M. & Sekizaki, S. 1986 Endothelium-dependent inhibition of platelet aggregation. Br. J. Pharmacol. 88, 411-415.
10. Baigent, C. & Patrono, C. 2003 Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease. Arthritis Rheum. 48, 12-20. (doi:10.1002/art.10738)
11. Barbacanne, M. A., Rami, J., Michel, J. B., Souchard, J. P., Philippe, M., Besombes, J. P., Bayard, F. & Arnal, J. F. 1999 Estradiol increases rat aorta endothelium-derived relaxing factor (EDRF) activity without changes in endothelial NO synthase gene expression: possible role of decreased endothelium-derived superoxide anion production. Cardiovasc. Res. 41, 672-681. (doi:10.1016/S0008-6363(98)00254-5)
12. Beckman, J. S., Beckman, T. W., Chen, J., Marshall, P. A. & Freeman, B. A. 1990 Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl Acad. Sci. USA 87, 1620-1624.
13. Belton, O. A., Duffy, A., Toomey, S. & Fitzgerald, D. J. 2003 Cyclooxygenase isoforms and platelet vessel wall interactions in the apolipoprotein E knockout mouse model of atherosclerosis. Circulation 108, 3017-3023. (doi:10.1161/01.CIR.0000104565.78013.AD)
14. Beltran, B., Orsi, A., Clementi, E. & Moncada, S. 2000 Oxidative stress and S-nitrosylation of proteins in cells. Br. J. Pharmacol. 129, 953-960.
15. Beltran, B., Quintero, M., Garcia-Zaragoza, E., O'Connor, E., Esplugues, J. V. & Moncada, S. 2002 Inhibition of mitochondrial respiration by endogenous nitric oxide: a critical step in Fas signaling. Proc. Natl Acad. Sci. USA 99, 8892-8897. (doi:10.1073/pnas.092259799)
16. 1 from the rat stomach. Nature 216, 873-876.
17. Bernal-Mizrachi, C. et al. 2005 Vascular respiratory uncoupling increases blood pressure and atherosclerosis. Nature 435, 502-506. (doi:10.1038/ nature03527)
18. Binz, C. 1891 Vorlesungen Ueber Pharmakologie. Berlin, Germany.
19. Bombardier, C. et al. 2000 Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N. Engl. J. Med. 343, 1520-1528. (doi:10.1056/NEJM200011 233432103)
20. Boo, Y. C. & Jo, H. 2003 Flow-dependent regulation of endothelial nitric oxide synthase: role of protein kinases. Am. J. Cell Physiol. 285, C499-C508.
21. Bresalier, R. S. et al. 2005 Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N. Engl. J. Med. 352, 1092-1102. (doi:10.1056/NEJMoa050493)
22. Brosnan, J. 2004 Vascular NAD(P)H oxidase as a novel therapeutic target in vascular disease. Drug News Perspect. 17, 429-434. (doi:10.1358/dnp.2004.17. 7.863701)
23. Brouet, A., Sonveaux, P., Dessy, C., Moniotte, S., Balligand, J. L. & Feron, O. 2001 Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins. Circ. Res. 89, 866-873.
24. Brown, G. C. 1999 Nitric oxide and mitochondrial respiration. Biochim. Biophys. Acta 1411, 351-369.
25. Brown, G. C. & Cooper, C. E. 1994 Nanomolar concentrations of nitric oxide reversibly inhibit synaptosomal respiration by competing with oxygen at cytochrome oxidase. FEBS Lett. 356, 295-298. (doi:10.1016/0014-5793(94)01290-3)
26. Bult, H., Boeckxstaens, G. E., Pelckmans, P. A., Jordaens, F. H., Van-Maercke, Y. M. & Herman, A. G. 1990 Nitric oxide as an inhibitory non-adrenergic, non-cholinergic neurotransmitter. Nature 345, 346-347. (doi:10.1038/345346a0)
27. Bunting, S., Gryglewski, R., Moncada, S. & Vane, J. R. 1976 Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and celiac arteries and inhibits platelet aggregation. Prostaglandins 12, 897-913. (doi:10.1016/0090-6980(76)90125-8)
28. Burch, J. W., Baenziger, N. L., Stanford, N. & Majerus, P. W. 1978a Sensitivity of fatty acid cyclooxygenase from human aorta to acetylation by aspirin. Proc. Natl Acad. Sci. USA 75, 5181-5184.
29. Burch, J. W., Stanford, N. & Majerus, P. W. 1978b Inhibition of platelet prostaglandin synthetase by oral aspirin. J. Clin. Invest. 61, 314-319.
30. Burleigh, M. E. et al. 2002 Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptor-deficient mice. Circulation 105, 1816-1823. (doi:10.1161/01.CIR.0000014927.74465.7F)
31. Cai, H. & Harrison, D. G. 2000 Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ. Res. 87, 840-844.
32. Capone, M. L. et al. 2004 Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. Circulation 109, 1468-1471. (doi: 10.1161/01.CIR.0000124715. 27937.78)
33. Carr, A. & Frei, B. 2000 The role of natural antioxidants in preserving the biological activity of endothelium-derived nitric oxide. Free Radic. Biol. Med. 28, 1806-1814. (doi:10.1016/S0891-5849(00)00225-2)
34. Cassina, A. & Radi, R. 1996 Differential inhibitory action of nitric oxide and peroxynitrite on mitochondrial electron transport. Arch. Biochem. Biophys. 328, 309-316. (doi:10. 1006/abbi.1996.0178)
35. Catella-Lawson, F. et al. 1999 Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics and vasoactive eicosanoids. J. Pharmcol. Exp. Ther. 289, 735-741.
36. Cayatte, A. J., Du, Y., Oliver-Krasinski, J., Lavielle, G., Verbeuren, T. J. & Cohen, R. A. 2000 The thromboxane receptor antagonist S18886 but not aspirin inhibits atherogenesis in apoE-deficient mice: evidence that eicosanoids other than thromboxane contribute to atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 20, 1724-1728.
37. Cellek, S. 2000 Nitrergic-noradrenergic interaction in penile erection: a new insight into erectile dysfunction. Drugs Today 36, 135-146.
38. Cellek, S., Rodrigo, J., Lobos, E., Fernandez, P., Serrano, J. & Moncada, S. 1999 Selective nitrergic neurodegeneration in diabetes mellitus-a nitric oxide-dependent phenomenon. Br. J. Pharmacol. 128, 1804-1812. (doi:10.1038/sj. bjp.0702981)
39. Chance, B., Sies, H. & Boveris, A. 1979 Hydroperoxide metabolism in mammalian organs. Physiol. Rev. 59, 527-605.
40. 2. Science 296, 539-541. (doi:10.1126/science.1068711)
41. Cheung, R. T., Pei, Z., Feng, Z. H. & Zou, L. Y. 2002 Cyclooxygenase-1 gene knockout does not alter middle cerebral artery occlusion in a mouse stroke model. Neurosci. Lett. 330, 57-60. (doi:10.1016/S0304-3940(02) 00738-3)
42. Chyu, K. Y., Dimayuga, P., Zhu, J., Nilsson, J., Kaul, S., Shah, P. K. & Cercek, B. 1999 Decreased neointimal thickening after arterial wall injury in inducible nitric oxide synthase knockout mice. Circ. Res. 85, 1192-1198.
43. Cleeter, M. W., Cooper, J. M., Darley-Usmar, V. M., Moncada, S. & Schapira, A. H. 1994 Reversible inhibition of cytochrome c oxidase, the terminal enzyme of the mitochondrial respiratory chain, by nitric oxide. Implications for neurodegenerative diseases. FEBS Lett. 345, 50-54. (doi:10.1016/0014- 5793(94)00424-2)
44. Clementi, E., Brown, G. C., Feelisch, M. & Moncada, S. 1998 Persistent inhibition of cell respiration by nitric oxide: crucial role of S-nitrosylation of mitochondrial complex I and protective action of glutathione. Proc. Natl Acad. Sci. USA 95, 7631-7636. (doi:10.1073/pnas.95.13.7631)
45. Clementi, E., Brown, G. C., Foxwell, N. & Moncada, S. 1999 On the mechanism by which vascular endothelial cells regulate their oxygen consumption. Proc. Natl Acad. Sci. USA 96, 1559-1562. (doi:10.1073/pnas.96.4.1559)
46. Cocks, T. M., Angus, J. A., Campbell, J. H. & Campbell, G. R. 1985 Release and properties of endothelium-derived relaxing factor (EDRF) from endothelial cells in culture. J. Cell. Physiol. 123, 310-320. (doi:10.1002/jcp.1041230304)
47. Craven, L. L. 1953 Experiences with aspirin (acetylsalicylic acid) in the nonspecific prophylaxis of coronary thrombosis. Mississippi Valley Med. J. 75, 38-44.
48. Crunkhorn, P. & Willis, A. L. 1971 Cutaneous reactions to intradermal prostaglandins. Br. J. Pharmacol. 41, 49-56.
49. Cullen, L., Kelly, L., Connor, S. O. & Fitzgerald, D. J. 1998 Selective cyclooxygenase-2 inhibition by nimesulide in man. J. Pharmacol. Exp. Ther. 287, 578-582.
50. De Caterina, R. et al. 1985 Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function. Eur. Heart J. 6, 409-417.
51. Deguchi, T. 1977 Endogenous activating factor for guanylate cyclase in synaptosomal-soluble fraction of rat brain. J. Biol. Chem. 252, 7617-7619.
52. Deguchi, T. & Yoshioka, M. 1982 L-Arginine identified as an endogenous activator for soluble guanylate cyclase from neuroblastoma cells. J. Biol. Chem. 257, 10 147-10 151.
53. Desai, K. M., Zembowicz, A., Sessa, W. C. & Vane, J. R. 1991 Nitroxergic nerves mediate vagally induced relaxation in the isolated stomach of the guinea pig. Proc. Natl Acad. Sci. USA 88, 11 490-11 494.
54. Di Rosa, M., Giroud, J. P. & Willoughby, D. A. 1971 Studies on the mediators of the acute inflammatory response induced in rats in different sites by carrageenan and turpentine. J. Pathol. 104, 15-29. (doi:10.1002/path. 1711040103)
55. Dogne, J. M. et al. 2004 New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators. Curr. Med. Chem. 11, 1223-1241.
56. Drazen, J. M. 2005 COX-2 inhibitors-a lesson in unexpected problems. N. Engl. J. Med. 352, 1131-1132. (doi:10.1056/NEJMe058038)
57. Droge, W. 2002 Free radicals in the physiological control of cell function. Physiol. Rev. 82, 47-95.
58. Dzau, V. J. 2001 Theodore Cooper lecture: tissue angiotensin and pathobiology of vascular disease: a unifying hypothesis. Hypertension 37, 1047-1052.
59. Egan, K. M., Lawson, J. A., Fries, S., Koller, B., Rader, D. J., Smyth, E. M. & FitzGerald, G. A. 2004 COX-2-derived prostacyclin confers atheroprotection on female mice. Science 306, 1954-1957. (doi:10.1126/science. 1103333)
60. Egan, K. M., Wang, M., Lucitt, M. B., Zukas, A. M., Pure, E., Lawson, J. A. & FitzGerald, G. A. 2005 Cyclooxygenases, thromboxane and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 111, 334-342. (doi:10.1161/01.CIR.0000153386.95356.78)
61. Ferreira, S. H. 1972 Prostaglandins, aspirin-like drugs and analgesia. Nat. New Biol. 240, 200-203.
62. Ferreira, S. H. & Moncada, S. 1971 Inhibition of prostaglandin synthesis augments the effects of sympathetic nerve stimulation on the cat spleen. Br. J. Pharmacol. 43, 419P-420P.
63. Ferreira, S. H., Moncada, S. & Vane, J. R. 1971 Indomethacin and aspirin abolish prostaglandin release from the spleen. Nat. New Biol. 231, 237-239.
64. Ferreira, S. H., Moncada, S. & Vane, J. R. 1973 Some effects of inhibiting endogenous prostaglandin formation on the responses of the cat spleen. Br. J. Pharmacol. 47, 48-58.
65. Fichtlscherer, S., Dimmeler, S., Breuer, S., Busse, R., Zeiher, A. M. & Fleming, I. 2004 Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease. Circulation 109, 178-183. (doi:10.1161/01.CIR. 0000105763.51286.7F)
66. FitzGerald, G. A. 2003 Parsing an enigma: the pharmacodynamics of aspirin resistance. Lancet 361, 542-544. (doi:10. 1016/S0140-6736(03)12560-3)
67. FitzGerald, G. A. & Patrono, C. 2001 The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 345, 433-442. (doi:10.1056/ NEJM200108093450607)
68. FitzGerald, G. A., Smith, B., Pedersen, A. K. & Brash, A. R. 1984 Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N. Engl. J. Med. 310, 1065-1068.
69. Fitzgerald, D. J., Roy, L., Catella, F. & FitzGerald, G. A. 1986 Platelet activation in unstable coronary disease. N. Engl. J. Med. 315, 983-999.
70. Fleming, I. 2001 Cytochrome p450 and vascular homeostasis. Circ. Res. 89, 753-762.
71. Fleming, I. & Busse, R. 2004 The physiology of nitric oxide: control and consequences. Curr. Med. Chem. 3, 189-205.
72. Frangos, J. A., Eskin, S. G., McIntire, L. V. & Ives, C. L. 1985 Flow effects on prostacyclin production by cultured human endothelial cells. Science 227, 1477-1479.
73. Frantz, S. 2004 Vioxx risk could signify trouble in class. Nat. Rev. Drug Discov. 3, 899-900. (doi:10.1038/nrd1560)
74. 2 synthase (cyclooxygenase) in human monocytes. J. Biol. Chem. 265, 16 737-16 740.
75. Furchgott, R. F. 1988 Studies on relaxation of rabbit aorta by sodium nitrite: the basis for the proposal that the acid-activatable inhibitory factor from retractor penis is inorganic nitrite and the endothelium-derived relaxing factor is nitric oxide. In Vasodilatation: vascular smooth muscle, peptides, autonomic nerves and endothelium (ed. P. M. Vanhoutte), pp. 401-414. New York, NY: Raven Press.
76. Furchgott, R. J. 1990 The 1989 Ulf von Euler lecture. Studies on endothelium-dependent vasodilation and the endothelium-derived relaxing factor. Acta Physiol. Scand. 139, 257-270.
77. Furchgott, R. F. & Zawadzki, J. V. 1980 The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 288, 373-376. (doi:10. 1038/288373a0)
78. Furchgott, R. F., Cherry, P. D., Zawadzki, J. V. & Jothianandan, D. 1984 Endothelial cells as mediators of vasodilation of arteries. J. Cardiovasc. Pharmacol. 6, S336-S343.
79. Garcia-Cardena, G., Comander, J., Anderson, K. R., Blackman, B. R. & Gimbrone Jr, M. A. 2001 Biomechanical activation of vascular endothelium as a determinant of its functional phenotype. Proc. Natl Acad. Sci. USA 98, 4478-4485. (doi: 10.1073/pnas.071052598)
80. Garg, U. C. & Hassid, A. 1989 Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat vascular smooth muscle cells. J. Clin. Invest. 83, 1774-1777.
81. Garthwaite, J., Charles, S. L. & Chess-Williams, R. 1988 Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature 336, 385-388. (doi:10. 1038/336385a0)
82. Garthwaite, J., Garthwaite, G., Palmer, R. M. & Moncada, S. 1989 NMDA receptor activation induces nitric oxide synthesis from arginine in rat brain slices. Eur. J. Pharmacol. 172, 413-416. (doi:10.1016/0922-4106(89)90023-0)
83. Gibbs, J. S., Broberg, C. S. & Gatzoulis, M. A. 2004 Idiopathic pulmonary arterial hypertension: current state of play and new treatment modalities. Int. J. Cardiol. 97, 7-10. (doi:10.1016/j.ijcard.2004.08.003)
84. Gibson, A. & Mirzazadeh, S. 1989 Does an endogenous nitrovasodilator mediate NANC relaxations of the mouse anococcygeus muscle? Br. J. Pharmacol. 98, 617P.
85. G-monomethyl L-arginine on the response of the rat anococcygeus muscle to NANC nerve stimulation. Br. J. Pharmacol. 98, 1080-1082.
86. Grabowski, E. F., Jaffe, E. A. & Weksler, B. B. 1985 Prostacyclin production by cultured endothelial cell monolayers exposed to step increases in shear stress. J. Lab. Clin. Med. 105, 36-43.
87. Gryglewski, R. J., Bunting, S., Moncada, S., Flower, R. J. & Vane, J. R. 1976 Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins 12, 685-713. (doi:10.1016/0090-6980(76)90047-2)
88. Gryglewski, R. J., Moncada, S. & Palmer, R. M. J. 1986a Bioassay of prostacyclin and endothelium-derived relaxing factor (EDRF) from porcine aortic endothelial cells. Br. J. Pharmacol. 87, 685-694.
89. Gryglewski, R. J., Palmer, R. M. J. & Moncada, S. 1986b Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 320, 454-456. (doi:10.1038/320454a0)
90. Guzik, T. J., West, N. E., Black, E., McDonald, D., Ratnatunga, C., Pillai, R. & Channon, K. M. 2000 Vascular superoxide production by NAD(P)H oxidase: association with endothelial dysfunction and clinical risk factors. Circ. Res. 86, E85-E90.
91. Hagen, T., Taylor, C. T., Lam, F. & Moncada, S. 2003 Redistribution of intracellular oxygen in hypoxia by nitric oxide: effect on HIF1α. Science 302, 1975-1978. (doi:10. 1126/science.1088805)
92. Hamberg, M. & Samuelsson, B. 1973 Detection and isolation of an endoperoxide intermediate in prostaglandin biosynthesis. Proc. Natl Acad. Sci. USA 70, 899-903.
93. Hamberg, M., Svensson, J., Wakabayashi, T. & Samuelsson, B. 1974 Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. Proc. Natl Acad. Sci. USA 71, 345-349.
94. Hamberg, M., Svensson, J. & Samuelsson, B. 1975 Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl Acad. Sci. USA 72, 2994-2998.
95. Hanson, J. et al. 2005 In vitro and in vivo pharmacological characterization of BM-613 ([N-n-pentyl-N′-[2-(2-(4′- methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist. J. Pharmacol. Exp. Ther. 313, 293-301. (doi:10.1124/jpet.104.079301)
96. Hattori, Y., Nakanishi, N. & Kasai, K. 2002 Statin enhances cytokine-mediated induction of nitric oxide synthesis in vascular smooth muscle cells. Cardiovasc. Res. 54, 649-658. (doi:10.1016/S0008-6363(02)00266-3)
97. Heitzer, T., Yla-Herttuala, S., Luoma, J., Kurz, S., Munzel, T., Just, H., Olschewski, M. & Drexler, H. 1996 Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia. Role of oxidized LDL. Circulation 93, 1346-1353.
98. Hibbs Jr, J. B., Taintor, R. R. & Vavrin, Z. 1987 Macrophage cytotoxicity: role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science 235, 473-476.
99. 2-like activity during phagocytosis. Prostaglandins 12, 749-757. (doi:10.1016/0090-6980(76) 90050-2)
100. 2) on platelet adhesion to rabbit arterial subendothelium. Prostaglandins 16, 17-22. (doi:10.1016/0090-6980(78) 90197-1)
101. Higgs, G. A., Flower, R. J. & Vane, J. R. 1979 A new approach to anti-inflammatory drugs. Biochem. Pharmacol. 28, 1959-1961. (doi:10.1016/0006- 2952(79)90651-8)
102. Hink, U. et al. 2001 Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ. Res. 88, E14-E22.
103. Hippisley-Cox, J. & Coupland, C. 2005 Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. Br. Med. J. 330, 1366-1372.
104. G-nitro arginine inhibits non-adrenergic, non-cholinergic relaxation of human isolated corpus cavernosum. Acta Physiol. Scand. 141, 441-442.
105. Horn, E. M. & Barst, R. J. 2002 Treprostinil therapy for pulmonary artery hypertension. Expert Opin. Investig. Drugs 11, 1615-1622. (doi:10.1517/13543784.11.11.1615)
106. Huang, P. L., Huang, Z., Mashimo, H., Bloch, K. D., Moskowitz, M. A., Bevan, J. A. & Fishman, M. C. 1995 Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377, 239-242. (doi:10.1038/377239a0)
107. Ignarro, L. J. 1987 Contributions to a quest. Nature 330, 526. (doi:10.1038/330526c0)
108. Ignarro, L. J., Buga, G. M., Wood, K. S., Byrns, R. E. & Chaudhuri, G. 1987 Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl Acad. Sci. USA 84, 9265-9269.
109. Ignarro, L. J., Byrns, R. E. & Wood, K. S. 1988 Biochemical and pharmacological properties of endothelium-derived relaxing factor and its similarity to nitric oxide radical. In Vasodilatation: vascular smooth muscle, peptide, autonomic nerves and endothelium (ed. P. M. Vanhoutte), pp. 427-436. New York, NY: Raven Press.
110. Ignarro, L. J., Bush, P. A., Buga, G. M., Wood, K. S., Fukuto, J. M. & Rajfer, J. 1990 Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem. Biophys. Res. Commun. 170, 843-850. (doi: 10.1016/0006-291X(90)92168-Y)
111. Ishizuka, T., Matsui, T. & Kurita, A. 2003 Ramatroban, a TP receptor antagonist, improves vascular responses to acetylcholine in hypercholesterolemic rabbits in vivo. Eur. J. Pharmacol. 468, 27-35. (doi:10.1016/S0014-2999(03) 01626-1)
112. Iyengar, R., Stuehr, D. J. & Marletta, M. A. 1987 Macrophage synthesis of nitrite, nitrate and N-nitrosamines: precursors and role of the respiratory burst. Proc. Natl Acad. Sci. USA 84, 6369-6373.
113. Johnson, R. A. et al. 1976 The chemical structure of prostaglandin X (prostacyclin). Prostaglandins 12, 915-918.
114. Juhlin, L. & Michaelsson, G. 1969 Cutaneous vascular reactions to prostaglandins in healthy subjects and in patients with urticaria and atopic dermatitis. Acta Derm. Venereol. 49, 251-261.
115. Kawashima, S. & Yokoyama, M. 2004 Dysfunction of endothelial nitric oxide synthase and atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 24, 998-1005. (doi:10. 1161/01.ATV.0000125114.88079.96)
116. 2-like activity. J. Clin. Invest. 62, 892-895.
117. Knowles, R. G., Palacios, M., Palmer, R. M. J. & Moncada, S. 1989 Formation of nitric oxide from L-arginine in the central nervous system: a transduction mechanism for stimulation of the soluble guanylate cyclase. Proc. Natl Acad. Sci. USA 86, 5159-5162.
118. Knowles, R. G., Salter, M., Brooks, S. L. & Moncada, S. 1990 Anti-inflammatory glucocorticoids inhibit the induction by endotoxin of nitric oxide synthase in the lung, liver and aorta of the rat. Biochem. Biophys. Res. Commun. 172, 1042-1048. (doi:10.1016/0006-291X(90)91551-3)
119. 2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J. Clin. Invest. 114, 784-794. (doi:10.1172/JCI200421446)
120. 2 interaction in vivo. Regulation by aspirin and relationship with anti-thrombotic therapy. Thromb. Res. 13, 489-500. (doi:10.1016/0049-3848(78)90134-2)
121. Kubes, P., Suzuki, M. & Granger, D. N. 1991 Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl Acad. Sci. USA 88, 4651-4655.
122. Kuhlencordt, P. J., Gyurko, R., Han, F., Scherrer-Crosbie, M., Aretz, T. H., Hajjar, R., Picard, M. H. & Huang, P. L. 2001 Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation 104, 448-454.
123. Kwon, N. S., Nathan, C. F., Gilker, C., Griffith, O. W., Matthews, D. E. & Stuehr, D. J. 1990 L-Citrulline production from L-arginine by macrophage nitric oxide synthase. The ureido oxygen derives from dioxygen. J. Biol Chem. 265, 13 442-13 445.
124. Landmesser, U., Dikalov, S., Price, S. R., McCann, L., Fukai, T., Holland, S. M., Mitch, W. E. & Harrison, D. G. 2003 Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J. Clin. Invest. 111, 1201-1209. (doi:10.1172/ JCI200314172)
125. Landolfi, R., Marchioli, R., Kutti, J., Gisslinger, H., Tognoni, G., Patrono, C. & Barbui, T. 2004 Efficacy and safety of low-dose aspirin in polycythemia vera. N. Engl. J. Med. 350, 114-124. (doi:10.1056/NEJMoa035572)
126. Laufs, U. 2003 Beyond lipid-lowering: effects of statins on endothelial nitric oxide. Eur. J. Clin. Pharmacol. 58, 719-731.
127. Leone, A. M., Palmer, R. M. J., Knowles, R. G., Francis, P. L., Ashton, D. S. & Moncada, S. 1991 Constitutive and inducible nitric oxide synthases incorporate molecular oxygen into both nitric oxide and citrulline. J. Biol. Chem. 266, 23 790-23 795.
128. Levine, G. N., Frei, B., Koulouris, S. N., Gerhard, M. D., Keaney Jr, J. F. & Vita, J. A. 1996 Ascorbic acid reverses endothelial vasomotor dysfunction in patients with coronary artery disease. Circulation 93, 1107-1113.
129. Li, C. G. & Rand, M. J. 1989 Evidence for a role of nitric oxide in the neurotransmitter system mediating relaxation of the rat anococcygeus muscle. Clin. Exp. Pharmacol. Physiol. 16, 933-938.
130. Li, C. G. & Rand, M. J. 1991 Evidence that part of the NANC relaxant response of guinea-pig trachea to electrical field stimulation is mediated by nitric oxide. Br. J. Pharmacol. 102, 91-94.
131. 2 production by a non-phagocytic NAD(P)H oxidase causes oxidant injury. J. Biol. Chem. 276, 29 251-29 256. (doi:10. 1074/jbc.M102124200)
132. Li, W. G. et al. 2003 Activation of NAD(P)H oxidase by lipid hydroperoxides: mechanism of oxidant-mediated smooth muscle cytotoxicity. Free Radic. Biol. Med. 34, 937-946. (doi:10.1016/S0891-5849(03)00032-7)
133. Lin, M. I., Fulton, D., Babbitt, R., Fleming, I., Busse, R., Pritchard Jr, K. A. & Sessa, W. C. 2003 Phosphorylation of threonine 497 in endothelial nitric-oxide synthase coordinates the coupling of L-arginine metabolism to efficient nitric oxide production. J. Biol. Chem. 278, 44 719-44 726. (doi:10.1074/jbc.M302836200)
134. Lizasoain, I., Moro, M. A., Knowles, R. G., Darley-Usmar, V. & Moncada, S. 1996 Nitric oxide and peroxynitrite exert distinct effects on mitochondrial respiration which are differentially blocked by glutathione or glucose. Biochem. J. 314, 877-880.
135. Luscher, T. F., Tanner, F. C., Tschudi, M. R. & Noll, G. 1993 Endothelial dysfunction in coronary artery disease. Annu. Rev. Med. 44, 395-418. (doi:10.1146/annurev.me.44.020193.002143)
136. Mann, G. E., Yudilevich, D. L. & Sobrevia, L. 2003 Regulation of amino acid and glucose transporters in endothelial and smooth muscle cells. Physiol. Rev. 83, 183-252.
137. Mateo, J., Garcia-Lecea, M., Cadenas, S., Hernandez, C. & Moncada, S. 2003 Regulation of hypoxia-inducible factor-1α by nitric oxide through mitochondria-dependent and -independent pathways. Biochem. J. 376, 537-544. (doi:10.1042/BJ20031155)
138. McAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A. & FitzGerald, G. A. 1999 Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc. Natl Acad. Sci. USA 96, 272-277. (doi:10.1073/pnas.96.1.272)
139. McAllister, T. N., Du, T. & Frangos, J. A. 2000 Fluid shear stress stimulates prostaglandin and nitric oxide release in bone marrow-derived preosteoclast-like cells. Biochem. Biophys. Res. Commun. 270, 643-648. (doi:10.1006/bbrc.2000.2467)
140. McCall, T. B., Boughton-Smith, N. K., Palmer, R. M. J., Whittle, B. J. R. & Moncada, S. 1989 Synthesis of nitric oxide from L-arginine by neutrophils. Biochem. J. 261, 293-296.
141. McCormick, S. M., Whitson, P. A., Wu, K. K. & McIntire, L. V. 2000 Shear stress differentially regulates PGHS-1 and PGHS-2 protein levels in human endothelial cells. Ann. Biomed. Eng. 28, 824-833. (doi:10.1114/1.1289472)
142. Mellion, B. T., Ignarro, L. J., Ohlstein, E. H., Pontecorvo, E. G., Hyman, A. L. & Kadowitz, P. J. 1981 Evidence for the inhibitory role of guanosine 3′, 5′-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood 57, 946-955.
143. 2 interactions in haemostasis and thrombosis. Haemostasis 8, 252-265.
144. Moncada, S. & Erusalimsky, J. D. 2002 Does nitric oxide modulate mitochondrial energy generation and apoptosis? Nat. Rev. Mol. Cell Biol. 3, 214-220. (doi:10.1038/nrm762)
145. Moncada, S. & Higgs, E. A. 1993 The L-arginine-nitric oxide pathway. N. Engl. J. Med. 329, 2002-2012. (doi:10.1056/NEJM199312303292706)
146. 2, and prostacyclin. Pharmacol. Rev. 30, 293-331.
147. Moncada, S., Ferreira, S. H. & Vane, J. R. 1973 Prostaglandins, aspirin-like drugs and the oedema of inflammation. Nature 246, 217-219. (doi:10.1038/246217a0)
148. Moncada, S., Gryglewski, R., Bunting, S. & Vane, J. R. 1976a An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263, 663-665. (doi:10.1038/263663a0)
149. Moncada, S., Gryglewski, R. J., Bunting, S. & Vane, J. R. 1976b A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins 12, 715-733. (doi:10. 1016/0090-6980(76) 90048-4)
150. Moncada, S., Bunting, S., Mullane, K., Thorogood, P., Vane, J. R., Raz, A. & Needleman, P. 1977a Imidazole: a selective inhibitor of thromboxane synthetase. Prostaglandins 13, 611-618. (doi:10.1016/0090-6980(77)90232-5)
151. Moncada, S., Higgs, E. A. & Vane, J. R. 1977b Human arterial and venous tissues generate prostacyclin (prostaglandin X), a potent inhibitor of platelet aggregation. Lancet 1, 18-20. (doi:10.1016/S0140-6736(77)91655-5)
152. 2) by layers of the arterial wall. An explanation for the anti-thombotic properties of vascular endothelium. Thromb. Res. 11, 323-344. (doi:10.1016/0049-3848(77) 90185-2)
153. Moncada, S., Palmer, R. M. J. & Gryglewski, R. J. 1986 Mechanism of action of some inhibitors of endothelium-derived relaxing factor. Proc. Natl Acad. Sci. USA 83, 9164-9168.
154. Moncada, S., Palmer, R. M. J. & Higgs, E. A. 1989 Biosynthesis of nitric oxide from L-arginine. A pathway for the regulation of cell function and communication. Biochem. Pharmacol. 38, 1709-1715. (doi:10.1016/0006-2952(89) 90403-6)
155. Moncada, S., Palmer, R. M. J. & Higgs, E. A. 1991 Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol. Rev. 43, 109-142.
156. Morita, I. 2002 Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat. 68-69, 165-175. (doi:10.1016/S0090-6980(02)00029-1)
157. Morrison, F. S. & Baldini, M. G. 1969 Antigenic relationship between blood platelets and vascular endothelium. Blood 33, 46-56.
158. Mueck, A. O., Seeger, H., Deuringer, F. U. & Wallwiener, D. 2001 Effect of an estrogen/statin combination on biochemical markers of endothelial function in human coronary artery cell cultures. Menopause 8, 216-221.
159. Mueller, C. F., Laude, K., McNally, J. S. & Harrison, D. G. 2005 Redox mechanisms in blood vessels. Arterioscler. Thromb. Vasc. Biol. 25, 274-278. (doi:10.1161/01.ATV.0000149143.04821.eb)
160. Mukherjee, D., Nissen, S. E. & Topol, E. J. 2001 Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286, 954-959. (doi:10.1001/jama.286. 8.954)
161. 2S and cyclooxygenases in immediate and delayed prostanoid biosynthetic pathways. J. Biol. Chem. 274, 3103-3115. (doi:10.1074/jbc.274.5.3103)
162. Murata, T. et al. 1997 Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature 388, 678-682. (doi:10.1038/41780)
163. Muscara, M. N., Vergnolle, N., Lovren, F., Triggle, C. R., Elliott, S. N., Asfaha, S. & Wallace, J. L. 2000 Selective cyclo-oxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. Br. J. Pharmacol. 129, 1423-1430.
164. 2 from prostaglandin endoperoxides. Nature 261, 558-560. (doi:10.1038/261558a0)
165. Neunteufl, T., Heher, S., Katzenschlager, R., Wolfl, G., Kostner, K., Maurer, G. & Weidinger, F. 2000 Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am. J. Cardiol. 86, 207-210. (doi:10.1016/S0002-9149(00)00857-2)
166. Nijkamp, F. P., Flower, R. J., Moncada, S. & Vane, J. R. 1976 Partial purification of rabbit aorta contracting substance-releasing factor and inhibition of its activity by anti-inflammatory steroids. Nature 263, 479-482. (doi:10. 1038/263479a0)
167. Nisoli, E. et al. 2003 Mitochondrial biogenesis in mammals: the role of endogenous nitric oxide. Science 299, 896-899. (doi:10.1126/science.1079368)
168. Norwood, V. F., Morham, S. G. & Smithies, O. 2000 Postnatal development and progression of renal dysplasia in cyclooxygenase-2 null mice. Kidney Int. 58, 22791-2300. (doi:10.1046/j.1523-1755.2000.00413.x)
169. Nugteren, D. H. & Hazelhof, E. 1973 Isolation and properties of intermediates in prostaglandin biosynthesis. Biochim. Biophys. Acta 326, 448-461.
170. Nugteren, D. H., Beerthuis, R. K. & van Dorp, D. A. 1967 In Proc. Second Nobel Symp. (ed. S. Bergstrom & B. Samuelsson), pp. 45-50. Stockholm, Sweden: Nobel Foundation.
171. Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A., Parlow, J. L., Boyce, S. W. & Verburg, K. M. 2005 Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N. Engl. J. Med. 352, 1081-1091. (doi:10.1056/NEJMoa050330)
172. O'Grady, J. & Moncada, S. 1978 Aspirin: a paradoxical effect on bleeding time. Lancet 2, 780. (doi:10.1016/S0140-6736(78)92661-2)
173. Ohashi, Y. et al. 1998 Hypotension and reduced nitric oxide-elicited vasorelaxation in transgenic mice overexpressing endothelial nitric oxide synthase. J. Clin. Invest. 102, 2061-2071.
174. Okahara, K., Sun, B. & Kambayashi, J. 1998 Upregulation of prostacyclin synthesis-related gene expression by shear stress in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 18, 1922-1926.
175. Olesen, M., Kwong, E., Meztli, A., Kontny, F., Seljeflot, I., Arnesen, H., Lyngdorf, L. & Falk, E. 2002 No effect of cyclooxygenase inhibition on plaque size in atherosclerosis-prone mice. Scand. Cardiovasc. J. 36, 362-367. (doi:10.1080/140174302762659094)
176. Osanai, T., Fujita, N., Fujiwara, N., Nakano, T., Takahashi, K., Guan, W. & Okumura, K. 2000 Cross talk of shear-induced production of prostacyclin and nitric oxide in endothelial cells. Am. J. Physiol. Heart Circ. Physiol. 278, H233-H238.
177. Pace-Asciak, C. & Wolfe, L. S. 1971 Novel prostaglandin derivative formed from arachidonic acid by rat stomach homogenates. Biochemistry 10, 3657-3664. (doi:10.1021/bi00796a004)
178. Palacios-Callender, M., Quintero, M., Hollis, V. S., Springett, R. J. & Moncada, S. 2004 Endogenous NO regulates superoxide production at low oxygen concentrations by modifying the redox state of cytochrome c oxidase. Proc. Natl Acad. Sci. USA 101, 7630-7635. (doi:10.1073/pnas.0401723101)
179. Palmer, R. M. J. & Moncada, S. 1989 A novel citrulline-forming enzyme implicated in the formation of nitric oxide by vascular endothelial cells. Biochem. Biophys. Res. Commun. 158, 348-352. (doi:10.1016/S0006-291X(89)80219-0)
180. Palmer, R. M. J., Ferrige, A. G. & Moncada, S. 1987 Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327, 524-526. (doi:10.1038/327524a0)
181. Palmer, R. M. J., Ashton, D. S. & Moncada, S. 1988a Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 333, 664-666. (doi:10.1038/333664a0)
182. Palmer, R. M. J., Rees, D. D., Ashton, D. S. & Moncada, S. 1988b L-Arginine is the physiological precursor for the formation of nitric oxide in endothelium-dependent relaxation. Biochem. Biophys. Res. Commun. 153, 1251-1256. (doi:10.1016/S0006-291X(88)81362-7)
183. Patrono, C., Ciabattoni, G., Patrignani, P., Pugliese, F., Filabozzi, P., Catella, F., Davi, G. & Forni, L. 1985 Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 72, 1177-1184.
184. Pedersen, A. K. & FitzGerald, G. A. 1984 Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N. Engl. J. Med. 311, 1206-1211.
185. Persson, K., Igawa, Y., Mattiasson, A. & Andersson, K. E. 1992 Effects of inhibition of the L-arginine/nitric oxide pathway in the rat lower urinary tract in vivo and in vitro. Br. J. Pharmacol. 107, 178-184.
186. Piper, P. J. & Vane, J. R. 1969 Release of additional factors in anaphylaxis and its antagonism by anti-inflammatory drugs. Nature 223, 29-35.
187. Piper, P. J., Vane, J. R. & Wyllie, J. H. 1970 Inactivation of prostaglandins by the lungs. Nature 225, 600-604. (doi:10.1038/225600a0)
188. Poderoso, J. J., Carreras, M. C., Lisdero, C., Riobo, N., Schopfer, F. & Boveris, A. 1996 Nitric oxide inhibits electron transfer and increases superoxide radical production in rat heart mitochondria and submitochondrial particles. Arch. Biochem. Biophys. 328, 85-92. (doi:10. 1006/abbi.1996.0146)
189. Pritchard Jr, K. A., Ackerman, A. W., Gross, E. R., Stepp, D. W., Shi, Y., Fontana, J. T., Baker, J. E. & Sessa, W. C. 2001 Heat shock protein 90 mediates the balance of nitric oxide and superoxide anion from endothelial nitric oxide synthase. J. Biol. Chem. 276, 17621-17624. (doi:10. 1074/jbc.C100084200)
190. Radomski, M. W., Palmer, R. M. J. & Moncada, S. 1987a Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br. J. Pharmacol. 92, 181-187.
191. Radomski, M. W., Palmer, R. M. J. & Moncada, S. 1987b The anti-aggregating properties of vascular endothelium: interactions between prostacyclin and nitric oxide. Br. J. Pharmacol. 92, 639-646.
192. Rajagopalan, S., Kurz, S., Munzel, T., Tarpey, M., Freeman, B. A., Griendling, K. K. & Harrison, D. G. 1996 Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J. Clin. Invest. 97, 1916-1923.
193. 2+ levels and relaxation in the rat anococcygeus muscle. Eur. J. Pharmacol. 174, 297-299. (doi:10.1016/0014-2999(89)90325-7)
194. Reddy, K. G., Nair, R. N., Sheehan, H. M. & Hodgson, J. M. 1994 Evidence that selective endothelial dysfunction may occur in the absence of angiographic or ultrasound atherosclerosis in patients with risk factors for atherosclerosis. J. Am. Coll. Cardiol. 23, 833-843.
195. Rees, D. D., Palmer, R. M. J. & Moncada, S. 1989a Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc. Natl Acad. Sci. USA 86, 3375-3378.
196. Rees, D. D., Palmer, R. M. J., Hodson, H. F. & Moncada, S. 1989b A specific inhibitor of nitric oxide formation from L-arginine attenuates endothelium-dependent relaxation. Br. J. Pharmacol. 96, 418-424.
197. Rees, D. D., Higgs, E. A. & Moncada, S. 2000 Nitric oxide and the vessel wall. In Hemostasis and thrombosis (ed. R. W. Colman, J. Hirsh, V. J. Marder, A. W. Clowes & J. N. George), pp. 673-682. Philadelphia, PA: Lippincott Williams & Wilkins.
198. Ridker, P. M., Cook, N. R., Lee, I. M., Gordon, D., Gaziano, J. M., Manson, J. E., Hennekens, C. H. & Buring, J. E. 2005 A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N. Engl. J. Med. 352, 1293-1304. (doi:10.1056/NEJMoa050613)
199. Ross, R. 1999 Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340, 115-126. (doi:10.1056/NEJM 199901143400207)
200. Roth, G. J. & Majerus, P. W. 1975 The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J. Clin. Invest. 56, 624-632.
201. Rott, D., Zhu, J., Burnett, M. S., Zhou, Y. F., Zalles-Ganley, A., Ogunmakinwa, J. & Epstein, S. E. 2003 Effects of MF-tricyclic, a selective cyclooxygenase-2 inhibitor, on atherosclerosis progression and susceptibility to cytomegalovirus replication in apolipoprotein-E knockout mice. J. Am. Coll. Cardiol. 41, 1812-1819. (doi:10.1016/S0735-1097(03)00304-8)
202. Rubanyi, G. M. & Vanhoutte, P. M. 1986 Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factor. Am. J. Physiol. 250, H822-H827.
203. Samuelsson, B., Granstrom, E. & Hamberg, M. 1967 In Proc. Second Nobel Symp. (ed. S. Bergstrom & B. Samuelsson), pp. 31-44. Stockholm, Sweden: Nobel Foundation.
204. Schachinger, V., Britten, M. B. & Zeiher, A. M. 2000 Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101, 1899-1906.
205. Schafer, M., Schafer, C., Ewald, N., Piper, H. M. & Noll, T. 2003 Role of redox signaling in the autonomous proliferative response of endothelial cells to hypoxia. Circ. Res. 92, 1010-1015. (doi:10.1161/01.RES.0000070882. 81508.FC)
206. Schopfer, F. J., Baker, P. R. & Freeman, B. A. 2003 NO-dependent protein nitration: a cell signaling event or an oxidative inflammatory response? Trends Biochem. Sci. 28, 646-654. (doi:10.1016/j.tibs.2003.10.006)
207. Schweizer, M. & Richter, C. 1994 Nitric oxide potently and reversibly deenergizes mitochondria at low oxygen tension. Biochem. Biophys. Res. Commun. 204, 169-175. (doi:10.1006/bbrc.1994.2441)
208. Shyue, S. K., Tsai, M. J., Liou, J. Y., Willerson, J. T. & Wu, K. K. 2001 Selective augmentation of prostacyclin production by combined prostacyclin synthase and cyclooxygenase-1 gene transfer. Circulation 103, 2090-2095.
209. Silverstein, F. E. et al. 2000 Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA 284, 1247-1255. (doi:10.1001/jama.284.10.1247)
210. Singer, R. 1945 Acetylsalicylic acid, a probable cause for secondary post-tonsillectomy hemorrhage. Arch. Otolaryng. 42, 19-20.
211. Singer, H. A. & Peach, M. J. 1983 Endothelium-dependent relaxation of rabbit aorta. II. Inhibition of relaxation stimulated by methacholine and A23187 with antagonists of arachidonic acid metabolism. J. Pharmacol. Exp. Ther. 226, 796-801.
212. Smith, J. B. & Willis, A. L. 1971 Aspirin selectively inhibits prostaglandin production in human platelets. Nat. New Biol. 231, 235-237.
213. Smith, J. B., Ingerman, C., Kocsis, J. J. & Silver, M. J. 1974 Formation of an intermediate in prostaglandin biosynthesis and its association with the platelet release reaction. J. Clin. Invest. 53, 1468-1472.
214. Solomon, S. D. et al. 2005 Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med. 352, 1071-1080. (doi:10. 1056/NEJMoa050405)
215. Solzbach, U., Hornig, B., Jeserich, M. & Just, H. 1997 Vitamin C improves endothelial dysfunction of epicardial coronary arteries in hypertensive patients. Circulation 96, 1513-1519.
216. Spiekermann, S. et al. 2003 Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 107, 1383-1389. (doi:10.1161/01.CIR.0000056762.69302.46)
217. Stemerman, M. B. 1981 Vascular injury: platelets and smooth muscle cell response. Phil. Trans. R. Soc. B 294, 217-224.
218. Stroes, E., Kastelein, J., Cosentino, F., Erkelens, W., Wever, R., Koomans, H., Luscher, T. & Rabelink, T. 1997 Tetrahydrobiopterin restores endothelial function in hypercholesterolemia. J. Clin. Invest. 99, 41-46.
219. Stuehr, D., Pou, S. & Rosen, G. M. 2001 Oxygen reduction by nitric oxide synthases. J. Biol. Chem. 276, 14533-14536. (doi:10.1074/jbc.R100011200)
220. Svensson, J., Hamberg, M. & Samuelsson, B. 1975 Prostaglandin endoperoxides IX. Characterization of rabbit aorta contracting substance (RCS) from guinea pig lung and human platelets. Acta Physiol. Scand. 94, 222-228.
221. Taddei, S., Virdis, A., Mattei, P., Ghiadoni, L., Sudano, I. & Salvetti, A. 1996 Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation 94, 1298-1303.
222. Tateson, J. E., Moncada, S. & Vane, J. R. 1977 Effects of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins 13, 389-397. (doi:10. 1016/0090-6980(77)90019-3)
223. 2. J. Clin. Invest. 102, 1994-2001.
224. Ting, H. H., Timimi, F. K., Boles, K. S., Creager, S. J., Ganz, P. & Creager, M. A. 1996 Vitamin C improves endothelium-dependent vasodilatation in patients with non-insulin-dependent diabetes mellitus. J. Clin. Invest. 97, 22-28.
225. Topper, J. N., Cai, J., Falb, D. & Gimbrone Jr, M. A. 1996 Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc. Natl Acad. Sci. USA. 93, 10417-10422. (doi:10.1073/pnas.93.19.10417)
226. Turrens, J. F. 2003 Mitochondrial formation of reactive oxygen species. J. Physiol. 552, 335-344. (doi:10.1113/jphysiol.2003.049478)
227. Usdin, S. 2005 Calming the COX-2 furor. BioCentury 13, A1-A6.
228. Vallance, P., Collier, J. & Moncada, S. 1989 Effects of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet 2, 997-1000. (doi:10.1016/S0140-6736(89)91013-1)
229. Vane, J. R. 1964 The use of isolated organs for detecting active substances in the circulating blood. Br. J. Pharmacol. 23, 360-373.
230. Vane, J. R. 1971 Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat. New Biol. 231, 232-235.
231. Vanhoutte, P. M. 1987 The end of the quest? Nature 327, 459-460. (doi:10.1038/327459a0)
232. Vargaftig, B. B. & Dao, N. 1971 Release of vasoactive substances from guinea-pig lungs by slow-reacting substance c and arachidonic acid. Its blockade by nonsteroid anti-inflammatory agents. Pharmacology 6, 99-108.
233. Vasquez-Vivar, J., Kalyanaraman, B., Martasek, P., Hogg, N., Masters, B. S., Karoui, H., Tordo, P. & Pritchard Jr, K. A. 1998 Superoxide generation by endothelial nitric oxide synthase: the influence of cofactors. Proc. Natl Acad. Sci. USA 95, 9220-9225. (doi:10.1073/pnas.95.16.9220)
234. Virdis, A. & Schiffrin, E. L. 2003 Vascular inflammation: a role in vascular disease in hypertension? Curr. Opin. Nephrol. Hypertens. 12, 181-187. (doi:10.1097/00041552-200303000-00009)
235. Von der Leyen, H. E. & Dzau, V. J. 2001 Therapeutic potential of nitric oxide synthase gene manipulation. Circulation 103, 2760-2765.
236. Wagner, A. H., Kohler, T., Ruckschloss, U., Just, I. & Hecker, M. 2000 Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler. Thromb. Vasc. Biol. 20, 61-69.
237. Walshe, T. E., Ferguson, G., Connell, P., O'Brien, C. & Cahill, P. A. 2005 Pulsatile flow increases the expression of eNOS, ET-1 and prostacyclin in a novel in vitro coculture model of the retinal vasculature. Invest. Ophthalmol. Vis. Sci. 46, 375-382. (doi:10.1167/iovs.04-0806)
238. Weiner, C. P., Lizasoain, I., Baylis, S. A., Knowles, R. G., Charles, I. G. & Moncada, S. 1994 Induction of calcium-dependent nitric oxide synthases by sex hormones. Proc. Natl Acad. Sci. USA 91, 5212-5216.
239. Williams, T. J. & Morley, J. 1973 Prostaglandins as potentiators of increased vascular permeability in inflammation. Nature 246, 215-217. (doi:10.1038/246215a0)
240. Willis, A. L. 1969 Release of histamine, kinin and prostaglandin during carrageenin-induced inflammation in the rat. In Prostaglandins, peptides and amines (ed. P. Mantegazza & E. W. Horton), pp. 31-38. New York, NY: Academic Press.
241. Willis, A. L., Vane, F. M., Kuhn, D. C., Scott, C. G. & Petrin, M. 1974 An endoperoxide aggregator (Lass), formed in platelets in response to thrombotic stimuli: purification, identification and unique biological significance. Prostaglandins 8, 453-507. (doi:10.1016/0090-6980(74)90062-8)
242. Wink, D. A., Cook, J. A., Krishna, M. C., Hanbauer, I., De Graff, W., Gamson, J. & Mitchell, J. B. 1995 Nitric oxide protects against alkyl peroxide-mediated cytotoxicity: further insights into the role nitric oxide plays in oxidative stress. Arch. Biochem. Biophys. 319, 402-407. (doi:10. 1006/abbi.1995.1310)
243. Worrall, B. B. & Johnston, K. C. 2000 Antiplatelet therapy in secondary stroke prevention. Curr. Atheroscler. Rep. 2, 104-109.
244. Xie, W. L., Chipman, J. G., Robertson, D. L., Erikson, R. L. & Simmons, D. L. 1991 Expression of a mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc. Natl Acad. Sci. USA 88, 2692-2696.
245. Xu, W., Charles, I. G. & Moncada, S. 2005 Nitric oxide: orchestrating hypoxia regulation through mitochondrial respiration and the endoplasmic reticulum stress response. Cell Res. 15, 63-65.
246. Yang, S., Bae, L. & Zhang, L. 2000 Estrogen increases eNOS and NOx release in human coronary artery endothelium. J. Cardiovasc. Pharmacol 36, 242-247. (doi:10.1097/00005344-200008000-00015)
247. Yu, I. S. et al. 2004 TXAS-deleted mice exhibit normal thrombopoiesis, defective hemostasis, and resistance to arachidonate-induced death. Blood 104, 135-142. (doi:10. 1182/blood-2003-10-3661)